Entera Bio (ENTX) Q3 2024 earnings summary

Executive summary

• Focused on developing oral peptide therapies for chronic conditions, with lead candidates EB613 for osteoporosis and EB612 for hypoparathyroidism; preparing for a Phase 3 study for EB613 pending FDA endpoint qualification.

• Advanced EB613, the first oral PTH (1-34) tablet for osteoporosis, with new comparative data presented at ASBMR 2024.

• Progressed oral GLP-1/glucagon and GLP-2 tablet programs, with positive PK/PD results and ongoing pre-IND validation; collaboration with OPKO Biologics on oral GLP-2 and OXM programs showed positive preclinical results, with additional data expected in 2024.

• Strengthened clinical and scientific advisory board with global experts.

• No material impact from ongoing Middle East conflicts, though risks remain due to regional instability.

Financial highlights

• Revenue for the nine months ended September 30, 2024 was $99,000, all from a research services agreement; no product sales revenue.

• Net loss for the nine months ended September 30, 2024 was $7.2 million, compared to $6.9 million in the prior year period.

• Net loss for Q3 2024 was $3.0 million ($0.08 per share), compared to $2.4 million ($0.08 per share) in Q3 2023.

• Cash and cash equivalents as of September 30, 2024 were $6.9 million, expected to fund operations into Q3 2025.

• Accumulated deficit reached $111.6 million as of September 30, 2024.

Outlook and guidance

• Current cash is expected to fund operations into Q3 2025, covering ongoing R&D, regulatory expenses, and collaborative research.

• Additional funding will be required to initiate the Phase 3 study for EB613; delays or inability to secure funding could impact development timelines.

• Anticipates FDA's decision on SABRE regulatory endpoint for osteoporosis drugs in January 2025, which could impact EB613's phase 3 pathway.

• Plans to present further data on oral OXM and advance multiple programs into clinical phases by 2025.